Crinetics Pharmaceuticals
CRNX • NASDAQ
Crinetics Pharmaceuticals is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO R. Scott Struthers, with a market cap of $3.5B.
CEOR. Scott Struthers
Next Earnings
Upcoming earnings announcement for Crinetics Pharmaceuticals
Date
Thursday, May 7, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$1.22
Revenue Estimate
$8.1M
Earnings History
Past 12 earnings reports for Crinetics Pharmaceuticals
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 26, 2026 | Q4 2025 | -$1.29Est: -$1.37 | +5.8% | $6.2MEst: $4.6M | +33.1% |  10-K |
| Nov 6, 2025 | Q3 2025 | -$1.38Est: -$1.26 | -9.5% | $143.0KEst: $1.3M | -89.1% | 10-Q |
| Aug 7, 2025 | Q2 2025 | -$1.23Est: -$1.11 | -10.8% | $1.0MEst: $2.3M | -55.8% | 10-Q |
| May 8, 2025 | Q1 2025 | -$1.04Est: -$0.95 | -9.5% | $361.0KEst: $100.0K | +261.0% | 10-Q |
| Feb 27, 2025 | Q4 2024 | -$0.88Est: -$0.89 | +1.1% | -Est: $727.3K | -100.0% | 10-K |
| Nov 12, 2024 | Q3 2024 | -$0.96Est: -$0.91 | -5.5% | -Est: $240.0K | -100.0% | 10-Q |
| Aug 8, 2024 | Q2 2024 | -$0.94Est: -$0.86 | -9.3% | $399.0KEst: $460.0K | -13.3% | 10-Q |
| May 9, 2024 | Q1 2024 | -$0.93Est: -$0.81 | -14.8% | $640.0KEst: $260.0K | +146.2% | 10-Q |
| Feb 28, 2024 | Q4 2023 | -$0.90Est: -$0.86 | -4.7% | -Est: $260.0K | -100.0% | 10-K |
| Nov 7, 2023 | Q3 2023 | -$1.01Est: -$0.91 | -11.0% | $346.0KEst: $120.0K | +188.3% | — |
| Aug 8, 2023 | Q2 2023 | -$0.94Est: -$0.86 | -9.3% | $988.0KEst: $560.0K | +76.4% | 10-Q |
| May 4, 2023 | Q1 2023 | -$0.85Est: -$0.82 | -3.7% | $2.7MEst: $300.0K | +793.0% | — |